Successful treatment with sofosbuvir and daclatasvir plus ribavirin in acute hepatitis C-infected patient with hepatic decompensation

被引：1

作者：

Wu, Sih-Hsien ^{[1
]}

Chao, Chi-Jen ^{[1
,2
]}

Huang, Yi-Hsiang ^{[1
,2
]}

Hou, Ming-Chih ^{[1
,2
]}

机构：

[1] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, 201 Sect 2,Shih Pai Rd, Taipei 112, Taiwan

[2] Natl Yang Ming Univ, Sch Med, Fac Med, Taipei, Taiwan

来源：

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION | 2019年 / 82卷 / 07期

关键词：

Acute hepatitis C; Direct acting antiviral agent; Hepatic decompensation; VIRUS GENOTYPE 1; B-VIRUS; ASIAN PATIENTS; HCV INFECTION; SINGLE-ARM; OPEN-LABEL; LEDIPASVIR; SUPERINFECTION; EPIDEMIOLOGY; INDIVIDUALS;

D O I：

10.1097/JCMA.0000000000000107

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment of chronic hepatitis C virus infection has evolved rapidly in recent years due to the invention of interferon-free direct antiviral agents (DAAs). However, evidence and recommendations for acute hepatitis C (AHC) virus infection by DAAs are still limited, especially for those whose disease presents with hepatic decompensation. Here, we report a case with genotype 1b AHC virus infection, complicated by hepatic decompensation and the patient received sofosbuvir and daclatasvir plus low dose ribavirin for 12 weeks. Serum hepatitis C virus RNA significantly declines after therapy and became undetectable at week 8 and it remained undetectable at 12 weeks after finishing therapy; sustained virological response was impressed. Our findings support that combination of sofosbuvir and daclatasvir plus ribavirin can be used for genotype 1b, AHC virus infection patients with overt hepatic decompensation.

引用

页码：595 / 598

页数：4

共 28 条

[21] Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial [J].